Charles River Laboratories Q2 2026 earnings show a quarter of modest top-line growth paired with a major portfolio realignment for the Wilmington, Massachusetts-based drug development partner. Charles River Laboratories International, Inc. (NYSE: CRL) reported second-quarter revenue of $1.00 billion for the period ended June 27, 2026, along with a GAAP loss per share of $(0.03) and non-GAAP earnings per share of $3.02, according to the company’s official second-quarter results released on August 5, 2026.
Total revenue declined 2.7% from $1.03 billion in the second quarter of 2025, but organic revenue increased 0.1%, the highest organic growth rate the company has posted since the third quarter of 2023. Growth in the Discovery and Safety Assessment (DSA) and Manufacturing Solutions segments offset a decline in the Research Models and Services (RMS) segment. The non-GAAP operating margin rose 420 basis points sequentially to 20.5%, while the GAAP operating margin held essentially flat sequentially at 11.9%, up from 9.7% in the prior-year quarter.
A central theme of the Charles River Laboratories Q2 2026 earnings release is guidance. The company raised its 2026 outlook for both revenue and non-GAAP earnings per share, citing improving demand in the DSA segment and better-than-expected results in Manufacturing Solutions. Organic revenue guidance moved up by 150 basis points at the midpoint, and non-GAAP earnings-per-share guidance increased by $0.25 at the midpoint versus the outlook issued on May 7, 2026.
Portfolio simplification is another defining feature of the Charles River Laboratories Q2 2026 earnings period. In May 2026, [INTERNAL LINK: Charles River Laboratories divestiture and portfolio strategy page, suggested anchor: “completed the divestitures”] of certain European Discovery Services sites along with its CDMO and Cell Solutions businesses, a step management described as sharpening the company’s focus on regulated testing. The company also repurchased $100 million of common stock in the second quarter at an average price of $174 per share, part of a broader capital-return effort under its board-approved buyback authorization.
Segment Performance Behind the Charles River Laboratories Q2 2026 Earnings
The segment generated revenue of $209.5 million, down 1.8% from $213.3 million a year earlier, with organic revenue falling 1.4% on softer demand for small research models and research model services in North America, partially offset by stronger demand in China. GAAP operating margin for the segment improved to 17.3% from 16.8%, largely due to lower amortization tied to the divested Cell Solutions business, while the non-GAAP operating margin slipped to 24.5% from 25.3% on lower volume and an unfavorable geographic mix.
Within the Charles River Laboratories Q2 2026 earnings breakdown, the company’s largest, posted revenue of $606.5 million, down 1.9% from $618.0 million, though organic revenue rose 0.2% on higher study volume for regulated safety assessment work. GAAP operating margin expanded to 20.5% from 19.9%, helped by lower amortization from the divested European sites and reduced legal costs tied to a resolved non-human primate supply matter. Non-GAAP operating margin eased to 25.6% from 27.4% on higher study-related direct costs.
Executive Commentary Accompanying the Charles River Laboratories Q2 2026 Earnings
Birgit Girshick, Chief Executive Officer, said the company made excellent progress in the quarter executing its Pathway to Purpose strategy, noting that management is actively evaluating opportunities to modernize the company and drive greater efficiency while strengthening its drug-development portfolio centered on regulated testing. Girshick also pointed to the DSA segment’s strongest net book-to-bill ratio in nearly four years, describing the improvement in demand as broad-based across global biopharmaceutical and small and mid-sized biotechnology clients.
Alongside the results, Charles River highlighted new collaborations intended to deepen client relationships and modernize operations. The company joined Eli Lilly’s TuneLab AI/ML platform, contributing non-clinical testing expertise to support drug discovery and R&D modernization efforts. It also began working with Arovella Therapeutics to provide in vitro Next Generation Sequencing services, a capability added through the PathoQuest acquisition, to advance Arovella’s cancer treatment programs. Separately, Charles River introduced an AI-enabled digital pathology workflow designed to improve study turnaround times and pathologist efficiency.
2026 Guidance Update Following the Charles River Laboratories Q2 2026 Earnings
Under its updated outlook, Charles River now expects reported revenue growth of (3.5)% to (2.5)% for 2026, versus a prior range of (5.5)% to (4.0)%, with organic revenue growth guided to 0.0% to 1.0%. GAAP earnings-per-share guidance was reduced to $3.05–$3.35 from $5.35–$5.85, a change management attributed primarily to the net loss recorded on the CDMO and Cell Solutions divestiture. Non-GAAP earnings-per-share guidance was raised to $11.15–$11.45 from $10.80–$11.30. The company said second-quarter investment gains tied to its deferred compensation plan are expected to be largely offset by a higher full-year tax rate, with a negligible net effect on non-GAAP earnings per share for the year.
Balance Sheet and Capital Allocation in the Charles River Laboratories Q2 2026 Earnings
Total assets stood at $7.53 billion as of June 27, 2026, up from $7.14 billion at year-end 2025, with goodwill rising to $3.08 billion, partly reflecting acquisition activity including the Cambodia NHP supplier deal. Cash and cash equivalents were $192.0 million, and long-term debt, net and finance leases totaled $2.62 billion. Year to date, Charles River repurchased 1.7 million shares for $300.0 million, and as of quarter-end had $700.0 million remaining under the $1.0 billion stock repurchase authorization approved by its board on October 29, 2025.
Q2 2026 Financial Performance vs. Q2 2025
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Total revenue | $1,004.1M | $1,032.1M | -2.7% reported / +0.1% organic |
| GAAP diluted EPS | $(0.03) | $1.06 | NM |
| Non-GAAP diluted EPS | $3.02 | $3.12 | -3.2% |
| GAAP operating margin | 11.9% | 9.7% | +220 bps |
| Non-GAAP operating margin | 20.5% | 22.1% | -160 bps |
| Net income (loss) to common shareholders | $(1.5)M | $52.3M | NM |
| Non-GAAP net income | $146.2M | $154.0M | -5.0% |
Segment Revenue and Margin Breakdown (Q2 2026)
| Segment | Revenue | YoY Reported | Organic Growth | GAAP Op. Margin | Non-GAAP Op. Margin |
|---|---|---|---|---|---|
| Research Models and Services (RMS) | $209.5M | -1.8% | -1.4% | 17.3% (vs 16.8%) | 24.5% (vs 25.3%) |
| Discovery and Safety Assessment (DSA) | $606.5M | -1.9% | +0.2% | 20.5% (vs 19.9%) | 25.6% (vs 27.4%) |
| Manufacturing Solutions | $188.1M | -6.3% | +1.3% | 34.9% (vs 6.0%) | 37.8% (vs 32.8%) |
